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Abstract  
BACKGROUND: IL-13 is one of many cytokines responsible for the chronic inflammation of 
asthma.  
AIM: The aim of this study was to determine the effect of combined therapy ICS/LABA and 
ICS/LABA plus Montelukast in patients with uncontrolled severe persistent asthma by analyzing of 
serum IL-13 and FEV1 before the treatment and after 6 months of therapy. 
MATERIAL AND METHODS: In study we included two groups. First group with 27 patients were 
treated with ICS/LABA. Second group with 29 patients were treated with ICS/LABA plus 
Montelukast. In each of them were measured serum IL-13 levels by the ELISA method and FEV1 
before and after 6 months of treatment. Results were statistically analyzed according to the 
Wilcoxon Pairs Test and T-test. 
RESULTS: The obtained results in both groups showed that the serum IL-13 before the start of 
therapy were much higher and after 6 months of treatment significantly reduces their value, which 
in the second group were more expressed. The difference in the average value of FEV1 in both 
groups before and after therapy was statistically significant. 
CONCLUSION: Treatment with ICS/LABA plus Montelukast proved superior compared to therapy 
of ICS/LABA in patients with uncontrolled severe persistent asthma and allows achievement of well 
controlled of asthma with subjective clinical improvement.  
 
 
 
 
 
Introduction 
 
If the 20-th century was underlined with an 
"explosion" of allergic diseases and asthma, the 21-th 
century is already called epidemic century for allergic 
diseases and asthma. Asthma is a worldwide problem 
and also is one of the most common chronic diseases 
worldwide —300 millions or 7.2% patients suffered 
from asthma. Prevalence was increasing in many 
countries, especially in children — 6% and in adult 
10%. There are 250,000 deaths annually. It is 
estimated that the number of people with asthma will 
grow by more than 100 million by 2025 [1-4]. In the 
Republic of Macedonia 100,000 or 5% of the 
population suffer from asthma [5, 6]. 
Asthma is a chronic inflammatory disorder of 
the airways in which many cells and cellular elements 
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play a role (mast cells, eosinophils, T lymphocytes, 
macrophages, neutrophils, and epithelial cells).  
These mediators act on cells in the airway, leading to 
contraction of smooth muscle, oedema due to plasma 
leakage and mucus plugging. The chronic 
inflammation is associated with airway 
hypersponsiveness that leads to recurrent episodes of 
wheezing, breathlessness, chest tightness and 
coughing, particularly at night or in the early morning. 
These episodes are usually associated with 
widespread, but variable, airflow obstruction within the 
lung that is often reversible either spontaneously or 
with treatment [1, 7, 8]. 
In this chronic inflammation are involve more 
than 100 mediators and the Interleukins take central 
place in this inflammation [9, 10]. The interleukins are 
cytokines that stimulate the proliferation and 
differentiation of immune cells. IL-1 activates T cells, 
IL-2 stimulates the proliferation of antigen-activated T 
and B cells; IL-4, IL-5 and IL-6 stimulated proliferation 
and differentiation of B cells; interferon-gamma (IFNγ) 
activates macrophages while IL-3, IL-7, and (GM-
CSF) stimulate hematopoiesis [11, 12]. 
T cells play a key role in coordinating the 
immune response in asthma. The key to the 
functioning of T cells is a molecule that binds to the 
antigen: T cells receptor. Generally the T cells which 
have the CD4 + act as helper cells (Th2-Ly), and 
CD8+ act as cytotoxic cells (Tc-Ly). CD4 + helper 
cells, differentiate into subpopulations of T cells in 
Th1, Th2, Th9, Th17, Th22 and T follicular effectors 
cell. Th2 cells produce, IL-4, IL-5, IL-9, IL-13, GM-
CSF and IL-25, IL-31, IL-33 that are responsible for 
chronic eosinophilic inflammation, inflammation in 
allergic diseases, including and asthma [13, 16]. 
Interleukin 13 (IL-13) is one of many cytokines 
responsible for the chronic inflammation of asthma. IL-
13 is synthesized by activated Th2 CD4 and CD8 cells 
in response to antigen specific stimulus. It has a 
similar function as IL-4. This is due to the ability to 
connect to a common receptor IL4R [16, 17]. 
Patients with asthma who have increase 
values of serum IL-13, lead to airway 
hyperresponsiveness, mucus hypersecretion, 
activation of fibroblasts and hyperplasia and 
hypertrophy of smooth muscle of the airways and if 
they do not use preventive anti-asthma treatment, 
may cause irreversible airway remodelling [18].
 
The National Asthma Education and 
Prevention Program have classified asthma as: 
intermittent, mild persistent, moderate persistent and 
severe persistent. These classifications are based on 
severity, which is determined by symptoms and lung 
function tests. You should be assigned to the most 
severe category in which any feature occurs [19].
 
Asthma is considered severe persistent if 
without treatment any of the following are true [19]. 
Symptoms: occur throughout each day, severely limit 
daily physical activities, night time symptoms occur 
often, sometimes every night, lung function tests are 
abnormal (FEV1<60% or less of expected value), and 
Peak Expiratory flow (PEF) varies more than 30% 
from morning to afternoon.  
FEV1 - Forced expiratory volume in the first 
second is the maximal volume of air exhaled in the 
first second of a forced expiration from a position of 
full inspiration expressed. FEV1 should be measured 
from a series of at least three forced expiratory curves 
that have an acceptable start of test and are free from 
artefact, such as a cough. The largest FEV1 should 
be recorded after examining the data from all of the 
usable curves, even if they do not come from the 
same curve. The calculated values than are converted 
to a percentage of normal, based on date of birth, 
height, weight, gender and race. FEV1 is a marker for 
the degree of airway obstruction in asthma. 
Reversibility with the use of a bronchodilator is 
defined as an increase in FEV1 of 12% or 200 ml [19, 
20, 40]. 
The aim of this study was to determine the 
effect of double combined therapy of inhaled 
corticosteroid and long-acting beta agonist - 
ICS/LABA and triple combined therapy ICS/LABA plus 
LTRA: leukotriene receptor antagonist (Montelukast) 
in patients with uncontrolled severe persistent asthma 
by analyzing of IL-13 and FEV1 before and after 6 
months of therapy. 
 
 
Material and Methods 
 
We have examined 56 patients with a 
diagnosis of uncontrolled severe persistent asthma 
treated at the Clinic of Pulmonology and Allergology. 
The available subjects were divided at random into 
two groups. First group with 27 patients were treated 
with combined therapy of ICS/LABA (500/50 mcg-
twice daily). Second group with 29 patients were 
treated with ICS/LABA (500/50 mcg-twice daily) plus 
Montelukast (10 mg-daily).  
In each of them were measured serum IL-13 
levels by the ELISA method before the treatment and 
after 6 months of therapy at the Institute of 
Immunobiology and Human Genetics, Faculty of 
Medicine, Ss Cyril and Methodius University of 
Skopje. The reference values for IL-13 are 0 to 6.9 
pg/ml. Spirometry was done with spirometer Schiller 
SP-1 according to the standard methodology at the 
Clinic of Pulmonology and Allergology, Faculty of 
Medicine, Ss Cyril and Methodius University of 
Skopje. We were analyzed FEV1- Forced expiratory 
volume in the first second. 
Inclusion Criteria: uncontrolled severe 
persistent asthma patients. The classification was 
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according to the actual version of the GINA guidelines 
(Global Initiative for Asthma) [1]   and Guidelines for 
the Diagnosis and Management of Asthma (EPR-3) of 
National Asthma Education Prevention Program 
(NAEPP) [19]. The age of the patients was 18-70 
years. 
Exclusion criteria: pregnancy, severe 
diseases of the immune, endocrine, haematological 
cardiac, renal, gastrointestinal, neurological system, 
psychiatric disorders, and neoplastic diseases. 
 
Statistical analysis 
The results were statistically analyzed 
according to the Wilcoxon Pairs Test. The 
significances value were taken p < 0.05 and a highly 
significant p < 0.01. 
 
 
Results  
 
First group with 27 patients were treated with 
combined therapy of ICS/LABA (500/50 mcg-twice 
daily). The average serum levels of IL-13 before the 
treatment were 907.37 ± 601.95 pg/ml and after 6 
months treatment were 527.47 ± 577.25 pg/ml. In this 
group were registered highly significant difference in 
the values of IL-13 before and after the treatment for a 
period of 6 months (G1: Z=3.19; p=0.0014) (Table 1).  
Table 1: Serum concentration of IL-13 in asthma patients 
treated with ICS/LABA (reference values 0 to 6.9 pg/ml) 
Therapy 
ICS/LABA 
Mean Std. Dev. Min-Max Median 25-75 Percentiles 
Before the 
treatment 
907.37 601.95 49.36-2067.32 787.3 368.77-1416.12 
After 6 months 527.47 577.25 0.16-2356.53 350.32 18.19-974.12 
Wilcoxon Pairs Test, Z = 3.19; p = 0.0014. 
 
In this group the average values of FEV1 
before the treatment were 37.33 ± 10.57%, and after 6 
months treatment they were increased on 57.33 ± 
13.27%. Statistically, this difference of 12.00 and is 
highly significant (p < 0.001), with significantly 
increased the values of FEV1. 
Table 2: The descriptive statistics – FEV1 in asthma patients 
treated with ICS/LABA   
Therapy 
ICS/LABA 
Mean Std. Dev. Min-Max Median 
Before the treatment 37.33 10.57 18.0 – 55.0 34.0 
After 6 months 57.33 13.27 32.0 – 68.0 57.0 
T = -12.54; p < 0.001**. 
 
Second group with 29 patients were treated 
with ICS/LABA (500/50 mcg-twice daily) plus 
Montelukast (10 mg-daily). Before the start of therapy 
with ICS/LABA (500/50 mcg-twice daily) plus 
Montelukast (10 mg-daily), were registered much 
higher values of serum IL-13 (the average was 
1028.21 ± 621.02 pg/ml) and after 6 months of 
treatment significantly reduces their value (the 
average was 252.21 ± 427.23 pg/ml),  Z = 4.7; p < 
0.001 (Table 3). 
Table 3: Serum concentration of IL-13 in asthma patients 
treated with ICS/LABA plus Montelukast (reference values 0 to 
6.9 pg/ml) 
Therapy 
ICS/LABA plus 
Montelukast 
 
Mean 
 
Std.Dev. 
 
Min-Max 
 
Median 
 
25-75 
percentiles 
Before the treatment 1028.21 621.02 67.35-2444.65 757.15 623.27-1514.29 
After 6 months 252.21 427.23 0.4-427.23 81.04 2.97-217.72 
Wilcoxon Pairs Test Z = 4.7; p < 0.001**. 
 
The patients who were treated with a 
combination of ICS/LABA and Montelukast, average 
values of FEV1 before the treatment were 36.76 ± 
10.26, and after 6 months therapy were 51.75 ± 
11.74. The difference in the average value before and 
after therapy 14.99 confirmed as statistically highly 
significant (p < 0.001) (Table 4). 
Table 4: The descriptive statistics – FEV1 in asthma patients 
treated with ICS/LABA plus Montelukast 
Therapy ICS/LABA plus 
Montelukast 
Mean Std. Dev. Min-Max Median 
Before the treatment 36.76 10.26 17.0-53.0 38.0 
After 6 months 51.75 11.74 32.0-73.0 53.0 
T = -10.125, p < 0.001**. 
 
 
Discussion 
The goal of asthma treatment is to achieve 
and maintain clinical total control. Combination 
therapy with ICS/LABA represents the gold standard 
in the treatment of asthma, safe and effective 
treatment which is recommended by the Global 
Initiative for Asthma in the treatment of uncontrolled 
severe persistent asthma in the step 3 and 4. 
Combination high dose of ICS/LABA, generally 
provides additional benefit but it is well recognized 
that not in all patients will achieve well-controlled 
asthma despite an appropriately high dose of ICS or 
ICS/ LABA combination therapy, in such patients, 
there is a need for additional add-on therapy such as 
treatment with a LTRA. Addition of a leukotriene 
receptor antagonist (LTRA) to patients who have 
considered to be insufficiently controlled resulted in a 
significant clinically improvement in asthma control, 
pulmonary function and quality of life [1, 19, 21-24]. 
In our study serum IL-13 was increased in all 
patients before the treatment. After 6 mounts therapy 
with combination of ICS/LABA in patients with 
uncontrolled severe persistent asthma we found 
decreases of serum IL-13, but added the Montelukast 
in this combination proved superior effect and allow 
achievement of total control of asthma with subjective 
clinical improvement. Unfortunately there are not 
available studies that analyze the level of IL -13 from 
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the effect of adding of montelukast to combination 
therapy ICS/LABA in patients with uncontrolled severe 
persistent asthma. 
It is known that the significant elevations in IL-
13 are found in the airways of patients with both 
allergic and nonallergic asthma [24].
 
In the study of 
Shimbori C, Montelukast treatment also decreased 
mRNA levels of IL-6, IL-10, IL-13, and TGF-β1, all of 
which were elevated in fibrotic lungs [26]. 
In several studies have confirmed that 
Montelukast add-on therapy with ICS or ICS/LABA 
treatment is effective for managing asthma in 
achieving control and reducing asthma symptoms in 
patients who were previously uncontrolled asthma 
symptoms with ICS or ICS/LABA treatment who had 
uncontrolled [27-29]. 
In our study the value of FEV1 at the start of 
therapy were lower in both groups and after 6 months 
of therapy confirmed as statistically significant 
improvement of lung function, increase especially in 
the group which used Montelukast and ICS/LABA.  
That is referenced in other studies when 
added to ICS, Montelukast induced further 
improvement in symptoms and pulmonary function, 
particularly in patients still symptomatic despite 
treatment with ICS. Although in short-term studies the 
combination of ICS plus LABA was more effective on 
symptoms and pulmonary function than ICS plus 
Montelukast [30-34].
  
Virchow et al in a recent article from an 
observational study on 1681 patients not controlled by 
ICS, or ICS plus LABA, showed that the addition of 
Montelukast improved both asthma control and 
asthma-related quality of life [21, 34].
 
 
In a 6-week study in symptomatic patients on 
high-dose ICS and short-acting b2-agonists, the 
addition of an LTRA significantly improved lung 
function and reduced exacerbations. 
 
In addition, in a 
smaller, open label study of 313 patients with 
insufficiently controlled patients on fixed combination 
therapy with ICS and LABAs, Dupont et al. observed 
an improvement in asthma symptoms and pulmonary 
function with add-on LTRA therapy after 2 months of 
therapy [21, 35, 36].
 
Many long-term studies on large groups of 
adult and pediatric patients, showed clinical and 
laboratory safety profile for Montelukast because no 
reported significant or considerable side effects 
observed for placebo or active control/usual care 
therapies. The safety profile of Montelukast did not 
change with long-term [36-39]. 
The relatively small number of participants 
may be considered a limitation factor. 
In conclusion, treatment with ICS/LABA plus 
Montelukast proved to be superior compared to 
therapy of ICS/LABA in patients with uncontrolled 
severe persistent asthma, leading to reduced 
inflammation and allows achievement of well 
controlled of asthma with subjective clinical 
improvement. The reduced values of IL-13 after 6 
month treatment with ICS/LABA led to clinical 
improvement, achieving good control of the disease 
and certainly able to reduce the dose of ICS/ LABA. 
This suggests that IL-13 is an important marker for 
monitoring of evolution and success of therapy in 
patients with asthma. 
In the future, research in the field of therapy in 
asthma, may be directed to discover a new molecules 
which specifically inhibited the activity of Th2 
cytokines, which actually indirectly reduce mediators 
and markers of inflammation. 
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